A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 351 participants.

Also called NCT07775404

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 351 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07775404
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China, Malaysia, Philippines, Thailand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07775404. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2028-04-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Acronym
Elecoglipron
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07775404
Content hash
6be0ff146f9f7415c52a2aff37ff57f23193b73f24910cd6ec10382bee0dadd8